Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an announcement.
Chimeric Therapeutics has announced that the Emory Winship Cancer Institute in Atlanta, Georgia, has joined its Phase 1/2 clinical trial for CHM CDH17, a novel CAR-T cell therapy targeting CDH17, a biomarker linked to poor prognosis in gastrointestinal tumors. This milestone marks the opening of the fourth and final clinical trial site in the USA, demonstrating Chimeric’s commitment to advancing cell therapy and enhancing its value to patients and shareholders.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian clinical stage cell therapy company focused on developing innovative cell therapies for cancer treatment. The company boasts a diversified portfolio that includes first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies, targeting various oncology disease areas with four clinical stage programs.
Technical Sentiment Signal: Buy
Current Market Cap: A$10.21M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.